Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 214

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 214
---
 at all. If the Company is unable to successfully refinance the Oaktree Loan,
the Company does not expect to have the ability to repay the amount in full. The Company believes that one of the other alternatives
available to it is the sale of one or more of the Company’s assets. There can be no assurance that any sale could be completed
on a timely basis or on terms acceptable to the Company. 

 22 

We have raised over $375,000,000
in gross proceeds through equity and debt financings since 2021. We may seek to obtain additional capital through equity or debt financings,
funding from corporate partnerships or licensing arrangements, sales of assets or other financing transactions. If we issue additional
equity or convertible debt securities to raise funds, our existing stockholders may experience substantial dilution, and the newly issued
equity or debt securities may have more favorable terms or rights, preferences and privileges senior to those of our existing stockholders.
If we raise additional funds through collaboration and licensing arrangements or sales of assets, we may have to relinquish potentially
valuable rights to our drug candidates or proprietary technologies, or grant licenses on terms that are not favorable to us. If we raise
funds by incurring additional debt, we may be required to pay significant interest expenses and our leverage relative to our earnings
or to our equity capitalization may increase. Obtaining commercial loans, assuming those loans would be available, would increase our
liabilities and future cash commitments and may impose restrictions on our activities, such as the financial and operating covenants.
Further, we may incur substantial costs in pursuing future capital and/or financing transactions, including investment banking fees,
legal fees, accounting fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses
in connection with certain securities we may issue, such as options, convertible notes and warrants, which would adversely impact our
financial results.

We have in the past participated and may in
the future participate in strategic transactions that could impact our liquidity, increase our expenses and distract our management.

From time to time, we consider
engaging in strategic transactions, such as out-licensing or in-licensing of compounds, drug candidates, drug products or technologies,
acquisitions of companies, and asset purchases. We may also consider a variety of different business arrangements in the future, including
strategic partnerships, joint ventures, spin-offs, carve-outs, restructurings, divestitures, business